The strong Phase 2 data in a difficult-to-treat population with FDA designations already in place significantly de-risks the path to approval. Triggers potential for near-term value inflection with planned 2026 BLA filing. Monitor for Phase 3 readout in breast cancer (DYNASTY-Breast02) later this year which could expand the market opportunity.
Price Chart
Executive Summary
BioNTech announced positive Phase 2 results for trastuzumab pamirtecan in HER2-expressing endometrial cancer, showing a 47.9% confirmed objective response rate and 8.1-month median progression-free survival. The data support advancement toward a 2026 BLA filing, with a confirmatory Phase 3 trial ongoing.
Key Facts
- Trastuzumab pamirtecan met primary efficacy endpoint in Phase 2 cohort of 145 patients with HER2-expressing, recurrent endometrial cancer
- Confirmed objective response rate was 47.9% in centrally tested patients (n=96) with median progression-free survival of 8.1 months
- Drug showed activity across all HER2 expression levels including IHC1+ and IHC2+, addressing high unmet need where standard chemo has only 15% response rate
- Safety profile was manageable with 46.9% grade 3 treatment-related adverse events and 4.8% grade 3 interstitial lung disease
- Fast Track and Breakthrough Therapy designations received from FDA in 2023; BLA planned for 2026 subject to regulatory feedback
Financial Impact
Significant potential revenue upside from a new oncology product in a high-unmet-need population with potential for accelerated approval. Phase 3 trial Fern-EC-01 ongoing.
Risk Factors
- Phase 3 confirmatory trial (Fern-EC-01) must validate these results for full approval
- Safety signals including 4.8% grade 3 ILD require careful risk-benefit assessment in broader populations
- Competition from other HER2-targeted therapies in development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001776985-26-000027 |
| Document: form6-ktpamecdatasgo202613.htm | 0001776985-26-000027 |
| Document: 0001776985-26-000027-index-headers.html | 0001776985-26-000027 |
| Document: 0001776985-26-000027-index.html | 0001776985-26-000027 |
| Document: 0001776985-26-000027.txt | 0001776985-26-000027 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $98.86 $98.00 | ▼ −0.87% | ▼ −0.98% | $96.61 (−2.28%) |
Sep 14, 2026 18d ago | Press Release | $98.86 $98.00 | ▼ −0.87% | ▼ −0.98% | $96.61 (−2.28%) |
Aug 28, 2026 5w ago | 6-K | $102.08 $103.76 | ▼ −1.65% | ▼ −1.54% | $96.61 (+5.36%) |
Aug 20, 2026 6w ago | 6-K | $110.89 $111.40 | ▲ +0.46% | ▼ −0.65% | $96.61 (−12.88%) |
Aug 11, 2026 7w ago | Institutional Cluster | $92.80 $92.75 | ▼ −0.05% | ▲ +0.35% | $96.61 (+4.10%) |
Aug 4, 2026 8w ago | 6-K | $91.35 $92.80 | ▼ −1.59% | ▼ −1.69% | $96.61 (−5.75%) |
Aug 3, 2026 8w ago | 6-K | $92.25 $92.80 | ▲ +0.60% | ▼ −1.43% | $96.61 (+4.72%) |
Aug 3, 2026 8w ago | Press Release | $92.25 $92.80 | ▲ +0.60% | ▼ −1.43% | $96.61 (+4.72%) |
Jul 29, 2026 9w ago | 6-K | $92.85 $91.19 | ▼ −1.79% | ▼ −5.41% | $96.61 (+4.04%) |
Jun 8, 2026 16w ago | 6-K | $85.50 $90.80 | ▲ +6.20% | ▲ +4.09% | $96.61 (+12.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access